

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252820 A1

(51) International Patent Classification:

C07D 215/36 (2006.01) A61K 31/4704 (2006.01)
C07D 401/12 (2006.01) A61P 29/00 (2006.01)
C07D 413/12 (2006.01)

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2021/036896

(22) International Filing Date:

10 June 2021 (10.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/037,001 10 June 2020 (10.06.2020) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: MILGRAM, Benjamin C.; c/o Amgen Inc., Law - Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). MARX, Isaac E.; c/o Amgen Inc., Law - Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). WANG, Haoxuan; c/o Amgen Inc., Law - Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US). CHERNEY, Alan H.; c/o Amgen Inc., Law - Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: LEMOINE, Elsa D.; AMGEN INC., Law - Patent Operations, One Amgen Center Drive, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: CYCLOBUTYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS



(57) Abstract: The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

WO 2021/252820 A1